Fonte: Journal of Infection. Unidade: FCF
Assuntos: VACINAS VIRAIS, VÍRUS EBOLA, ANTICORPOS, CRIANÇAS
ABNT
ALABI, Ayodele et al. Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub- Saharan African paediatric population: a randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon. Journal of Infection, v. 89, n. 4, p. 1-33 art. 106237, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.jinf.2024.106237. Acesso em: 03 nov. 2024.APA
Alabi, A., Kokou, K., Mahmoudou, S., Kavishna, R., Nakka, S. S., Rothenberger, S., et al. (2024). Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub- Saharan African paediatric population: a randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon. Journal of Infection, 89( 4), 1-33 art. 106237. doi:10.1016/j.jinf.2024.106237NLM
Alabi A, Kokou K, Mahmoudou S, Kavishna R, Nakka SS, Rothenberger S, Musangomunei FP, Olubiyi BF, Bie-Ondo JC, Kabwende AL, Velavan TP, Medaglini D, Nakaya HTI, Engler O, Harandi AM, Siegrist CA, Kremsner PG, Agnandji ST. Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub- Saharan African paediatric population: a randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon [Internet]. Journal of Infection. 2024 ; 89( 4): 1-33 art. 106237.[citado 2024 nov. 03 ] Available from: https://dx.doi.org/10.1016/j.jinf.2024.106237Vancouver
Alabi A, Kokou K, Mahmoudou S, Kavishna R, Nakka SS, Rothenberger S, Musangomunei FP, Olubiyi BF, Bie-Ondo JC, Kabwende AL, Velavan TP, Medaglini D, Nakaya HTI, Engler O, Harandi AM, Siegrist CA, Kremsner PG, Agnandji ST. Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub- Saharan African paediatric population: a randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon [Internet]. Journal of Infection. 2024 ; 89( 4): 1-33 art. 106237.[citado 2024 nov. 03 ] Available from: https://dx.doi.org/10.1016/j.jinf.2024.106237